Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPC1 | O15118 | 7/20 | 0.62 |
| ▸ | RAB9A | P51151 | 7/20 | 0.62 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.62 |
| ▸ | MEN1 | O00255 | 1/20 | 0.62 |
| ▸ | KDM4E | B2RXH2 | 5/20 | 0.60 |
| ▸ | SMN1; SMN2 | Q16637 | 5/20 | 0.60 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.60 |
| ▸ | HSD17B10 | Q99714 | 4/20 | 0.60 |
| ▸ | HPGD | P15428 | 4/20 | 0.60 |
| ▸ | MAPT | P10636 | 4/20 | 0.60 |
| ▸ | GLA | P06280 | 1/20 | 0.60 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.60 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.59 |
| ▸ | PTGS2 | P35354 | 4/20 | 0.56 |
| ▸ | PTGS1 | P23219 | 3/20 | 0.56 |
| ▸ | NPSR1 | Q6W5P4 | 4/20 | 0.56 |
| ▸ | USP2 | O75604 | 1/20 | 0.55 |
| ▸ | TSHR | P16473 | 1/20 | 0.55 |
| ▸ | XBP1 | P17861 | 1/20 | 0.55 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.55 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1930084 | 0.92 | L3MBTL1 (0.67) | NPC1RAB9AKMT2AKDM4ESMN1; SMN2 | |
| SCHEMBL1930392 | 0.86 | L3MBTL1 (0.62) | NPC1RAB9AKMT2AKDM4ESMN1; SMN2 | |
| SCHEMBL1931147 | 0.86 | L3MBTL1 (0.59) | NPC1RAB9AKMT2AKDM4ESMN1; SMN2 | |
| SCHEMBL1930755 | 0.85 | NPC1 (0.61) | NPC1RAB9AKMT2AKDM4ESMN1; SMN2 | |
| SCHEMBL1930503 | 0.85 | L3MBTL1 (0.55) | NPC1RAB9AKMT2AMEN1KDM4E | |
| SCHEMBL1928775 | 0.84 | NPC1 (0.67) | NPC1RAB9AKMT2AKDM4ESMN1; SMN2 | |
| SCHEMBL1930663 | 0.84 | L3MBTL1 (0.57) | NPC1RAB9AKMT2AKDM4ESMN1; SMN2 | |
| SCHEMBL5428698 | 0.84 | PTGS2 (0.80) | MAPTPTGS2PTGS1MT-CO2CA12 | |
| SCHEMBL14562098 | 0.84 | PTGS2 (0.80) | MAPTPTGS2PTGS1MT-CO2CA12 | |
| SCHEMBL1930507 | 0.83 | NPC1 (0.65) | NPC1RAB9AKMT2AMEN1KDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1968972-B1 | ARYL-ISOXAZOLO-4-YL-OXADIAZOLE DERIVATIVES | HOFFMANN LA ROCHE (CH) | 2012-11-28 | — | — | EP | claimed |
| US-7541372-B2 | Aryl-isoxazolo-4-yl-oxadiazole derivatives | HOFFMAN-LA ROCHE INC. (US) | 2009-06-02 | — | — | US | claimed |
| EP-1968972-A1 | ARYL-ISOXAZOLO-4-YL-OXADIAZOLE DERIVATIVES | F. Hoffmann-La Roche AG (CH) | 2008-09-17 | — | — | EP | claimed |
| US-20070161686-A1 | Aryl-isoxazolo-4-yl-oxadiazole derivatives | HOFFMANN-LA ROCHE INC. | 2007-07-12 | — | — | US | claimed |
| WO-2007071598-A1 | ARYL-ISOXAZOLO-4-YL-OXADIAZOLE DERIVATIVES | F. HOFFMANN-LA ROCHE AG (CH) | 2007-06-28 | — | — | WO | claimed |
| EP-1968972-B1 | ARYL-ISOXAZOLO-4-YL-OXADIAZOLE DERIVATIVES | HOFFMANN LA ROCHE (CH) | 2012-11-28 | — | — | EP | disclosed |
| US-7956074-B2 | Aryl-isoxazolo-4-yl-oxadiazole derivatives | HOFFMAN-LA ROCHE INC. (US) | 2011-06-07 | — | — | US | disclosed |
| US-20090197875-A1 | ARYL-ISOXAZOLO-4-YL-OXADIAZOLE DERIVATIVES | BUETTELMANN BERND | 2009-08-06 | — | — | US | disclosed |
| US-7541372-B2 | Aryl-isoxazolo-4-yl-oxadiazole derivatives | HOFFMAN-LA ROCHE INC. (US) | 2009-06-02 | — | — | US | disclosed |
| EP-1968972-A1 | ARYL-ISOXAZOLO-4-YL-OXADIAZOLE DERIVATIVES | F. Hoffmann-La Roche AG (CH) | 2008-09-17 | — | — | EP | disclosed |
| US-20070161686-A1 | Aryl-isoxazolo-4-yl-oxadiazole derivatives | HOFFMANN-LA ROCHE INC. | 2007-07-12 | — | — | US | disclosed |
| WO-2007071598-A1 | ARYL-ISOXAZOLO-4-YL-OXADIAZOLE DERIVATIVES | F. HOFFMANN-LA ROCHE AG (CH) | 2007-06-28 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090197875-A1 | ARYL-ISOXAZOLO-4-YL-OXADIAZOLE DERIVATIVES | GABRA5, GABRA4, GABRA3 | NPC1 1684/4885RAB9A 2522/4885KMT2A 2612/4885 |
| US-20070161686-A1 | Aryl-isoxazolo-4-yl-oxadiazole derivatives | GABRA5, GABRA4, GABRA3 | NPC1 1684/4885RAB9A 2522/4885KMT2A 2612/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.